Rivaroxaban also decreased the threat for complete venous thromboembolism or all lead to death likewise as for leading venous thromboembolism or venous thromboembolism associated death . In contrast with enoxaparin, dabigatran was not related to a different possibility of symptomatic deep vein thrombosis or pulmonary embolism . Dabigatran was related to a trend in the direction of a increased danger of complete venous thromboembolism or all trigger death than enoxaparin plus a equivalent risk of significant venous thromboembolism or venous thromboembolism relevant death . The risk of total venous thromboembolism or all result in death was similar involving dabigatran 220 mg and enoxaparin nonetheless it was increased together with the dabigatran 150 mg dose than with enoxaparin . Major venous thromboembolism or venous thromboembolism connected death didn’t vary considerably amongst the dabigatran 220 mg each day dose v enoxaparin or concerning the dabigatran 150 mg regular dose v enoxaparin . Apixaban decreased the risk of symptomatic deep vein thrombosis in contrast with enoxaparin but was related to a numerical maximize in circumstances of pulmonary embolism with borderline heterogeneity .
The results for pulmonary embolism have been homogeneous inside of the two pivotal scientific studies on complete knee replacement surgery , through which the risk of symptomatic pulmonary embolism with apixaban was substantially larger than that with enoxaparin . On the contrary, apixaban was related to a reduce risk of total venous thromboembolism or Tivozanib 475108-18-0 all induce death as well as a trend in direction of a reduce chance of major venous thromboembolism or venous thromboembolism linked death than enoxaparin. . Main security end result Rivaroxaban was associated with a significant boost in danger of clinically pertinent bleeding . Dabigatran didn’t show a significant boost compared with enoxaparin . The possibility was very similar inside the comparison of dabigatran 220 mg with enoxaparin bioactive small molecule library and dabigatran 150 mg with enoxaparin . About the contrary, apixaban was associated with a significantly lowered chance of clinically pertinent bleeding compared with enoxaparin . No evidence of statistical heterogeneity was found for this outcome among scientific studies evaluating rivaroxaban, dabigatran, or apixaban with enoxaparin. Secondary safety outcomes Rivaroxaban was connected with a non-significant trend in direction of a increased danger of major bleeding than was enoxaparin and clinically relevant non-major bleeding . In contrast with enoxaparin, dabigatran was related to a very similar threat of big bleeding and a non-significant trend in direction of a greater risk of clinically appropriate non-major bleeding . Apixaban showed a non-significant trend towards a minimal risk of major bleeding than did enoxaparin , which was during the restrict of statistical significance for clinically related non-major bleeding . No important trends have been identified in chance of death in between the brand new anticoagulants and enoxaparin.